How many investments has FemHealth Ventures made?

FemHealth Ventures has 29 tracked investments, 1 of which have exited, including 2 dated in the last 24 months.

What stage does FemHealth Ventures invest at?

FemHealth Ventures invests at the Seed, Series A stages.

What sectors does FemHealth Ventures focus on?

FemHealth Ventures focuses on Biotech, Digital Health, FemTech, Healthtech.

Where is FemHealth Ventures located?

FemHealth Ventures is headquartered in Short Hills, US.

Does FemHealth Ventures lead rounds?

FemHealth Ventures typically participates in rounds rather than leading them.

Who does FemHealth Ventures co-invest with?

FemHealth Ventures most often shares deals with Joyance Partners, Alumni Ventures, Ascension Ventures, among 122 tracked co-investors.

FemHealth Ventures

Venture capitalActively deployingoperating company · company profile

Short Hills · Seed–Series A · 10 people tracked

Also known as FEMHEALTH VENTURES MANAGEMENT LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into FemHealth Ventures

Paths you didn't know you had: your email and LinkedIn already hold routes to the FemHealth Ventures team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

FemHealth Ventures invests in women's health innovations, guided by its proprietary FemHealth Framework (first published 2019) that categorizes women's health conditions into three groups: those appearing only in women (e.g. endometriosis, PCOS, cervical cancer), mostly in women (e.g. breast cancer, lupus, multiple sclerosis), and differently in women (e.g. heart disease, diabetes, asthma). The firm emphasizes that biological sex differences at the cellular level mean diseases can present differently in women and require distinct treatment approaches. It views women's health as a large, underserved, high-growth market opportunity while seeking exceptional returns.

Invests inBiotech Digital Health FemTech Healthtech Global United States

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Seed–Series A

Short Hills, NJ, US

Leads rounds

Follows

Instruments

Equity

Founded

2019

Last 12 months

2 investments

Private fund assets

$102.4M

VC funds

Tracked investments

Acquisitions

Team · 10 people

from the firm's website

Maneesha Ghiya· Managing Partner· New York City Metropolitan Areain

Maneesha Ghiya, a healthcare investor driven by a life-threatening postpartum hemorrhage, has 25+ years in private and public healthcare investing and helped formalize the widely adopted 2019 three-category women's-health framework.

Sara Crown Star· Venture Partner· Chicago, Illinois, United Statesin

Sara Crown Star, President of SCS Innovations, brings company-building experience and a returns-first view treating women's health as an underappreciated economic opportunity across drugs, devices, diagnostics and digital health.

Greg Brown· Advisory Board - Healthcare Royalty Investing Pioneer· Houston, Texas, United Statesin

Gregory B. Brown, M.D. is CEO and a director of Memgen, Inc., a development-stage company working on next-generation viral immunotherapeutics including oncolytic viruses. He co-founded HCR Partners, a healthcare-focused asset management firm, and was previously a partner at Paul Capital Partners where he co-managed royalty investments; earlier he was co-head of investment banking and head of healthcare at Adams, Harkness & Hill and a biotechnology research analyst at Vector Securities International. Trained as a transplantation immunologist and thoracic and vascular surgeon, he holds a B.A. from Yale College, an M.D. from SUNY Upstate Medical Center, and an M.B.A. from Harvard Business School.

Nisha Chakravarty· Impact Executive / Wharton Lecturer· United Statesin

Nisha Chakravarty is an impact executive whose 20-year career spans the social sector, financial services, and publishing, with a focus on expanding access to education, healthcare, and employment through technology and market-based approaches. She currently serves as EVP at Safe Water Network, has founded social enterprises in Ethiopia, India, and Kenya, and previously held CFO and COO roles as well as finance and shared-services positions at Goldman Sachs, Lehman Brothers, Nomura India, TIME, and Scholastic. She lectures on social innovation at The Wharton School and holds an Ed.D. in Artificial Intelligence from the University of Pennsylvania, an M.A. from Columbia University, and a B.S.E. from The Wharton School.

Rache Simmons· Advisory Board - Breast Cancer Surgeon· New York Cityin

Rache Simmons is a breast cancer surgeon who has practiced breast surgery at Weill Cornell Medical Center/New York Presbyterian Hospital for three decades. She is a founding member and Past-President of the American Society of Breast Surgeons, and serves as Associate Dean of Diversity and Inclusion and inaugural Director of the Office of Women at Weill Cornell Medicine. She holds a bachelor's degree and MD from Duke University and an MBA from Cornell University's Johnson School of Business.

Randy Cohen· Advisory Board - HBS Professor· Cambridge, Massachusetts, United Statesin

Randy Cohen (Randolph B. Cohen), PhD, is the MBA Class of 1975 Senior Lecturer of Entrepreneurial Management at Harvard Business School, where he teaches finance and entrepreneurship and leads Field X, a course for MBA students starting businesses. He has previously served as an Associate Professor at HBS and a Visiting Associate Professor at MIT Sloan, and his research covers money manager selection, asset allocation, risk management, municipal securities, cryptocurrency, and longevity insurance. He has helped start and grow several businesses, mainly in investment management, and holds an AB in mathematics from Harvard College and a PhD in finance and economics from the University of Chicago.

Sean Ainsworth· Advisory Board - Biotech CEO· San Francisco, California, United Statesin

Sean Ainsworth is CEO and Chairman of the Board of Immusoft, with over 25 years in biotechnology and pharmaceuticals. He founded and led RetroSense Therapeutics, a gene therapy company sold to Allergan in 2016, and serves as Lead Independent Director at Ocuphire Pharma (Nasdaq: OCUP). He founded Ainsworth BioConsulting in 2004 and holds an MBA from Washington University in St. Louis and a BS in Microbiology from UC San Diego.

Stephan Oppenheimer· Advisory Board - Private Equity Investor· United Statesin

Stephan Oppenheimer is Managing Partner of Pontalba Capital, a private investment firm. He previously spent five years as a Partner at Moelis Capital Partners, where he oversaw the business services practice, and ten years with CCMP Capital (formerly JPMorgan Partners) in New York and London leading U.S. and international investments. He holds a B.S. in Electrical Engineering and an M.B.A. from the Darden Graduate School of Business, both from the University of Virginia.

Stephanie Wang· Investor· New York, New York, United Statesin

Stephanie Wang is an Investor at FemHealth Ventures focused on innovations in women's health. She previously worked as a consultant at ZS Associates, a healthcare-focused management consulting firm, advising pharmaceutical companies on R&D, pricing, value and access, and marketing. She holds a B.A. in Finance and Computer Science from New York University's Leonard N. Stern School of Business.

Susanne Seripiero· Executive Administrator· Woodbury, New York, United Statesin

Susanne Seripiero is the Executive Administrator at FemHealth Ventures, supporting operational functions. She previously served as Executive Assistant to the COO at the New York-based hedge fund Kingdon Capital, and holds a B.A. in English with a concentration in Secondary Education from Kean University.

What they invest in

from 26 of 29 portfolio companies

Healthtech ×23Biotech ×15Medical Devices ×15Digital Health ×5AI & Machine Learning ×4FemTech ×4Deep Tech ×2Robotics ×2

HQs:United States×21

Who they back

founder profiles across 16 portfolio companies

44%

solo founders

7 of 16 mapped founding teams

42%

repeat founders

of 19 founders with career history

Founding team size:solo founder×72 founders×43 founders×24+ founders×3

Where their founders studiedfrom 18 founders with education data

Duke University ×2Harvard T.H. Chan School of Public Health ×2Indian Institute of Technology, Delhi ×2Massachusetts Institute of Technology ×2

What their founders studiedfrom 18 founders with field-of-study data

Engineering ×6Economics ×4Business & Management ×3Finance & Accounting ×2Life Sciences ×2Mathematics & Statistics ×2

Where their founders worked beforefrom 19 founders with career history

Bridgewater Associates ×2Cornell ×2Parsagen Diagnostics, Inc. ×2

Accelerator rootsportfolio companies that came through a program

Y Combinator ×2

Investments · 29 tracked

founders shown can be your intro path

By year:2026 · 2 2024 · 1 2022 · 1 2021 · 1 2020 · 2 2018 · 18 dated

Raydiant Oxymetryraydiantoximetry.com in✓ verified

Raydiant Oximetry is developing technology to reduce complications and emergency interventions during childbirth.

Digital HealthFemTechHealthtechMedical DevicesSan Ramon, US

Neil P. Ray(Executive Officer, Director)in Michael Nagel(Chief Executive Officer)in

BoardCharles McDonald(Director)John Maroney(Director)

Co-investorsAvestria Ventures Band of Angels SteelSky Ventures Tri-Valley Ventures Bill & Melinda Gates Foundation Rhia Ventures +6 more

Trefoil Therapeuticstrefoiltherapeutics.com in✓ verified

Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.

BiotechHealthtechMedical DevicesSan Diego, US

David Eveleth(Executive Officer, Director)in Schalon Newton(Executive Officer)in

Board Christy Shaffer(Director)inRalph Bradshaw(Director)

Co-investorsExSight Ventures Hatteras Venture Partners Solasta Ventures Access Biotechnology Bios Partners Correlation Ventures +1 more

10Beauty10beauty.co in

10Beauty operates robotic manicure stations using single-use pod technology and proprietary nail-strengthening polishes.

ConsumerHealthtechRoboticsWestwood, US

Willie Litvack(Founder & General Partner)in Sean Tolkin(Founder & General Partner)in Alexander Shashou(Founder & CEO)in

Co-investorsAlumni Ventures Basecamp Fund Blue Ivy Ventures Centre Street Partners Formus Capital Good Friends +8 more

Alyssumtxalyssumtx.com in

Alyssum is a biotechnology company developing novel therapeutic drugs, with expertise in protein engineering, oncology, and clinical development.

BiotechDeep TechHealthtech

Tamara Agajanov(Head of Clinical Operations)inAditya Bardia(Head of Clinical Development & Chairman of Clinical Advisory Board)Richard Fahrner(Head of Management Team (CMC))inErmanno Gherardi(Head of Research)Shiladitya Sengupta(Head of Strategy & Translational Efforts)inPaul Theunissen(CFO)

AOA Dxaoadx.com in 𝕏Seed

AOA Dx develops a blood-based liquid biopsy platform using mass spectrometry and machine learning to detect ovarian cancer at early stages through tumor-associated biomarkers in serum.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesDenver, US

Oriana Papin-Zoghbi(Founder)in Alex Fisher(COO)in Anna Jeter(Founder)inOriana Zoghbi-Harb(Executive Officer, Director)Abigail Mcelhinny(Executive Officer)inRob Mayers(Recruiter)

Co-investorsAlleyCorp Good Growth Capital Joyance Partners Y Combinator Astia Aurum Venture Partners +37 more

BioAestheticsbio-aesthetics.com

BioAesthetics develops NACgraft, a cell-free, collagen-rich nipple-areolar complex graft that a surgeon applies so the patient's own cells integrate it into living nipple and areola tissue.

BiotechHealthtechMedical DevicesNew Materials

Juliana Blum(CEO & Director)Billy Heim(COO)in

Co-investorsHemi Ventures, Llc Joyance Partners New Orleans Startup Fund The Launch Place Babel Ventures IndieBio +1 more

Brixtonbrixtonbio.com

Brixton Bio develops Reneurx therapy, a treatment aimed at providing long-lasting pain relief for up to six months from a single administration.

BiotechMedical Devices

Charles Sidoti(Founder)in

Co-investorsAngel Physicians Fund Catalyst Health Ventures Excelestar Ventures Schooner Capital Sparta Group SV Health Investors

Cerclecercle.ai in

Cercle builds a platform that ingests and transforms healthcare data at scale into insights, with a focus on fertility and reproductive care.

AI & Machine LearningData & InfrastructureFemTechHealthtechSan Francisco, US

Andreas Melder(Co-founder & CEO)inDr. Irene Cuevas(Co-founder & Chief Scientist)Liya Sharif Lancia(Founder)in Pran Punniamoorthy(CTO)in Lucy Huang(COO)in

Co-investorsOutsiders Rogue Womens Fund

Evommuneevommune.com in

Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.

BiotechHealthtechPalo Alto, US

Luis Pena(President & Chief Executive Officer)inJanice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)

Co-investorsAndera Partners Avego BioScience Capital B Capital Group B4 Capital Beiersdorf Innovation Fund Longwood Fund +4 more

GammaTilegammatile.com in 𝕏Jun 2026 · $100M

GammaTile is an FDA-cleared, bioresorbable collagen tile embedded with radiation sources that is implanted during brain tumor removal surgery to deliver targeted radiation to remaining cancer cells.

BiotechHealthtechMedical Devices

David G. Brachman, MD, FASTRO(Co-Founder and Chief Technology Officer)Heyoung McBride, MD, MS, FASTRO(Co-Founder)Peter Nakaji, MD(Co-Founder)inEmad Youssef, MD(Co-Founder)Theresa Thomas, MS, CCRC(Co-Founder)Per Langoe(Chief Executive Officer)in

Co-investorsAccelmed Partners BlueStone Venture Partners Evidity Health Capital Gilde Healthcare MedTech Venture Partners MVM Life Science Partners +1 more

Gtmedtechgtmedtech.com 𝕏

GT Medical Technologies develops GammaTile, an implantable radiation therapy device for treating operable brain tumors.

BiotechHealthtechMedical Devices

Co-investorsAccelmed Partners BlueStone Venture Partners Evidity Health Capital

Gynesonicsgynesonics.com 𝕏acquired by Hologic

FemTechHealthtechMedical DevicesRedwood City, US

Christopher Owens(Executive Officer, Director)Darrin Uecker(Executive Officer, Director)

BoardKen Haas(Director)Jonathan MacQuitty(Director)in Mike Carusi(Director)inDoug Fisher(Director)

Co-investorsAmzak Health Bain Capital Life Sciences Endeavour Vision Kaiser Permanente Ventures Kluz Ventures Lightstone Ventures +6 more

Iantrekiantrekmed.com in

Iantrek develops micro-interventional ophthalmic surgical technologies focused on enhancing total outflow through the uveoscleral pathway to treat glaucoma.

BiotechHealthtechMedical DevicesElkins Park, US

Tsontcho Ianchulev(Executive Officer, Director)Sean Ianchulev(Founder & Chairman of the Board (CMO))inMichael Haydin(Executive Officer)

Board Jeffry K Weinhuff(Director)Farrell Tyson(Director)Stephen Bloch(Director)in

Co-investorsaMoon Visionary Ventures Canaan Partners Civilization Ventures Management, Llc JSD Capital, LLC US Venture Partners

IgGenix Inc.iggenix.com in

IgGenix is a clinical-stage biotechnology company focused on antibody discovery and development for allergies and immunological diseases.

AI & Machine LearningBiotechHealthtechSouth San Francisco, US

Kari Nadeau(Founder)Bruce Hironaka(Founder)Derek Croote(Founder)Stephen Quake(Founder)

Co-investorsKhosla Ventures Allerfund Ventures, Llc Global Brain Medical Incubator Japan K.K.ShangBay Capital LLC Alexandria +1 more

Imperative Care Incimperativecare.com in 𝕏

Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey.

HealthtechMedical DevicesCampbell, US

Farhad Khosravi(Executive Officer, Director)Matthew Garrett(Executive Officer)inCharles Alpuche(Executive Officer)Scott Elliott(Executive Officer)in

BoardJames Rogers(Director)Stacy Enxing Seng(Director)

Co-investorsAscension Ventures Bain Capital Life Sciences Catalio Capital Management, LP Delos Capital Lightstone Ventures

inSoma Bioinsomabio.comJun 2020

inSoma Bio develops biomaterial products for reconstruction plastic surgery, enabling surgeons to use patients' own tissue instead of synthetic implants and fillers for breast and facial reconstruction procedures.

BiotechHealthtechMedical DevicesDurham, US

Stefan Roberts(Founder)in Ashutosh Chilkoti(Founder)in

BoardScott Hollenbeck(Lead Medical Advisor, Co-Founder)inJuliana Blum(Director)Heather Brennan(Director)June S. Almenoff(Director)

Co-investorsDuke Capital Partners Y Combinator 360 Capital Asymmetry Ventures Deep Ventures Medblue +1 more

Kanvas Biokanvasbio.com in 𝕏

Kanvas Bio operates a platform for discovering, developing, and manufacturing live biotherapeutics based on the human gut microbiome.

BiotechDeep TechHealthtechMonmouth Junction, US

Matthew Cheng(Executive Officer, Director)in Hao Shi(Executive Officer, Director)in Iwijn De Vlaminck(Executive Officer, Director)in

Board Jason Pontin(Director)inJustin Smithline(Director)in

Co-investorsAlumni Ventures Bascom Ventures Boutique Venture Partners DCVC (Data Collective)Germin8 Ventures Kicker Ventures +4 more

Mendaeramendaera.com in 𝕏

Mendaera builds robotic technology, including its Focalist System for robotic-guided access and procedures such as transplant biopsy, to help healthcare providers perform reproducible clinical procedures.

Digital HealthHealthtechMedical DevicesRoboticsSan Mateo, US

Josh DeFonzo(Founder)inJason Wilson(Founder)

Co-investorsThreshold Ventures Founders Fund Lux Capital Averin Capital Overlap Holdings Sonder Capital +3 more

Microbiome Therapeutics in

HealthtechNew Orleans, US

Mark Heiman(Executive Officer)inDale Pfost(Executive Officer, Director, Promoter)

BoardDon Marvin(Director)Richard Montgomery(Director)Ross Barrett(Director)John Elstrott(Director, Promoter)

Co-investorsSofinnova Ventures Bayern Kapital DCVC (Data Collective)Pangaea Ventures Us Inc.

Nymbl Sciencenymblscience.comNov 2022 · $12M

HealthtechDenver, US

Edward Likovich(Executive Officer, Director)inJames Cook(Executive Officer, Director, Promoter)

BoardThomas Virden(Director)Ben Wire(Director)in Chris Saxman(Director)inRohit Seth(Director)

Co-investorsAllied Venture Partners Cobalt Ventures Forefront Venture Healthtech Capital Joyance Partners Rockies Venture Club +3 more

Ossium Healthossiumhealth.com in 𝕏May 2018

Ossium Health develops cellular therapies and bioengineered products for clinical use, leveraging adult stem cell technologies and advanced cell processing platforms.

BiotechHealthtechMedical DevicesSan Francisco, US

Kevin Caldwell(Founder)inDr. Woods(Chief Science Officer, Co-Founder, EVP, CLIA Laboratory Director)Sebastian Giwa(Director)in Erik Woods(Founder)in

Board William Trenchard(Director)inThomas Cycyota(Director)

Co-investorsAlumni Ventures First Round Capital General Catalyst Hemisphere Ventures LLC Manta Ray Ventures Mount Pleasant Ventures +4 more

Raydiantraydiant.com 𝕏Nov 2021 · $5M

Displai (Raydiant) provides digital signage, employee experience tools, and location analytics powered by AI for brick-and-mortar and enterprise businesses.

AI & Machine LearningEnterprise SoftwareRetail TechSaaSSan Francisco, US

Chester Ng(Executive Officer, Director)inBobby Marhamat(Executive Officer, Director)Tuan Ho(Founder)in

Board Jack Abraham(Executive Officer, Director)in

Co-investorsBeaconsfield Capital Bloomberg Beta Fernbrook Capital Management NextView Ventures Overton Venture Capital Transmedia Capital +12 more

Rejonirejoni.com inSep 2020

Rejoni is a company focused on uterine health, developing technology to address women's reproductive and gynecological health needs.

BiotechFemTechHealthtechMedical DevicesBedford, US

Amar Sawhney(Founder)inNICK SVENCER(Executive Officer, Director, Promoter)FARHAD KHOSRAVI(Executive Officer, Director, Promoter)

BoardTARA BUTLER(Executive Officer, Director, Promoter)

Co-investorsAscension Ventures Catalyst Health Ventures ClavystBio Delos Capital Iyengar Capital Partners Sparta Group +1 more

Reunion Neurosciencereunionneuro.com in 𝕏Jan 2024

Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.

BiotechDigital HealthMental HealthMorristown, US

Sahil V. Kirpekar(President and CEO)inGregory Mayes(Executive Officer, Director)Ellen Lubman(Director)Mark Pollack(Executive Officer)inNathan Bryson(Executive Officer)in Mark Theeuwes(Executive Officer)in

Co-investorsMitsui Global Investment MPM BioImpact Palo Santo VC Novo Holdings

Sequelsequelmedtech.com in

Sequel Med Tech develops wearable insulin delivery devices and precise drug delivery technology for people with diabetes and others, building on the legacy of the insulin pump.

Digital HealthHardwareHealthtechMedical DevicesManchester, US

Co-investorsAlumni Ventures Graph Ventures Great Oaks Venture Capital Growth Warrior Capital Javelin Venture Partners Long Journey Ventures +3 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Alyssum TherapeuticsGT Medical TechnologiesNextNewsOximetry

Exits · 1

1 acquisitions

Gynesonicsacq. by Hologic

Portfolio news

latest coverage across their companies

10Beauty Raises $23.5M in Funding

10Beauty · finsmes.com · Jul 2, 2026

Rejoni, Inc. Secures $25 Million in Financing to Accelerate the Juveena® Hydrogel System Toward FDA Approval and Launch

Rejoni · finance.yahoo.com · Jun 16, 2026

Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)

Reunion Neuroscience · finance.yahoo.com · Sep 16, 2025

Iantrek Raises $42 Million Series C to Launch AlloFlo™ Uveo, a Breakthrough Interventional Glaucoma Therapy

Iantrek · globenewswire.com · Aug 20, 2025

Frequently asked questions

How many investments has FemHealth Ventures made?: FemHealth Ventures has 29 tracked investments, 1 of which have exited, including 2 dated in the last 24 months.
What stage does FemHealth Ventures invest at?: FemHealth Ventures invests at the Seed, Series A stages.
What sectors does FemHealth Ventures focus on?: FemHealth Ventures focuses on Biotech, Digital Health, FemTech, Healthtech.
Where is FemHealth Ventures located?: FemHealth Ventures is headquartered in Short Hills, US.
Does FemHealth Ventures lead rounds?: FemHealth Ventures typically participates in rounds rather than leading them.
Who does FemHealth Ventures co-invest with?: FemHealth Ventures most often shares deals with Joyance Partners, Alumni Ventures, Ascension Ventures, among 122 tracked co-investors.

Media · Podcasts & interviews

featuring the team

Episode 186: Maneesha Ghiya of FemHealth Ventures - Amplifying Women in Healthcare and Beyond

Aoifinn Devitt · Maneesha Ghiya

Maneesha Ghiya & Yeenee Leri: FemHealth Ventures

Sarah Schwartz · Maneesha Ghiya

Images

Similar investors

Future Positive Capital

Future Positive Capital is a venture firm backing entrepreneurs building companies that address large-scale global challenges across health, sustainability and technology.

Lux Capital

Lux Capital is a venture capital firm that backs founders building transformative deep technologies, having been among the first investors in category-defining companies across AI, robotics, biotech, defense, and infrastructure.

$100K – $100M

Global Health Investment Corporation

Global Health Investment Corporation (GHIC) is a nonprofit that invests in life sciences and healthcare technology companies to accelerate the development and accessibility of products improving global public health and health equity.

MedMountain Ventures

MedMountain Ventures (MMV) is a physician-led venture capital firm founded by board-certified physicians that invests early in transformative healthcare companies aiming to improve patient outcomes and reform care delivery.

$500K – $5M

Pathway to Cures

Pathway to Cures (P2C) is the venture philanthropy fund of the National Bleeding Disorders Foundation, focused on funding the development of transformational therapies and technologies for inheritable blood and bleeding disorders.